alogliptin数据库.docVIP

Accession No: 36723 Main Details Drug Name World Status Pharma Status alogliptin benzoate Launched Active alogliptin DPP-IV inhibitors, Syrrx-1 DPP4 inhibitors, Takeda Nesina SYR 322 SYR-110322 SYR-322 SYR110322 SYR322 TAK-322 Vipidia Latest Change Updated On By Latest Change 27 Sep 2013 PT Additional Phase III trial (EXAMINE) results reported Company Status Data Originator Country Development Stage Takeda Japan Launched Licensee ? ? Furiex Pharmaceuticals USA Discontinued Sanofi France Registered Activity Data Therapy Description Code Status Antidiabetic A10B Launched Anorectic/Antiobesity A8A3 Preclinical Hypolipaemic/Antiatherosclerosis C10 Preclinical Pharmacology Description Code Protease/peptidase inhibitor PR- Dipeptide hydrolase inhibitor PEPT-D-HY- Dipeptidyl peptidase 4 (DPP IV) inhibitor PEPT-D4- Insulin secretagogue INS-SE+ Therapy Code Pharmacology Code A10BA8A3C10 PR-, PEPT-D-HY-, PEPT-D4-, INS-SE+PR-, PEPT-D-HY-, PEPT-D4-, INS-SE+PR-, PEPT-D-HY-, PEPT-D4-, INS-SE+ Route of Administration Route of Administration Code Alimentary, po A-PO Indication Status Hypercholesterolaemia Preclinical Obesity Preclinical Diabetes, Type 2 Launched Pharmacokinetics Human (25-800mg po) t1/2β - 12.4hr; Tmax - 1hr Chemical Data Origin of Material Code Description CH-SY Chemical, synthetic CAS Registry Number Molecular Weight Molecular Formula 850649-62-6 339.40 C25H27N5O4 Chemical Name Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-, monobenzoate Country Data Country Name Status Year Launched Licensing Op. Argentina Phase III Clinical Trial ? No Australia Pre-registration ? No Austria Registered ? No Belgium Registered ? No Brazil Pre-registration ? No Canada Phase III Clinical Trial ? No Chile Phase III Clinical Trial ? No China Registered ? No Colombia Pre-registration ? No Denmark Registered ? No Finland Registered ? No